Clinical trials · Denver, CO
Locally Advanced clinical trials in Denver
We’re tracking 47 recruiting locally advanced studies with a site in or near Denver — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Denver
- NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Denver, ColoradoAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Denver, ColoradoAges 18 years+ - NCT06307795RecruitingPhase 1
New drug for advanced solid tumors with MET, ROS1, or NTRK changes
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
Denver, ColoradoAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Denver, ColoradoAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Denver, ColoradoAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Denver, ColoradoAges 18 years+ - NCT06415487RecruitingPhase 1
Testing a new cell therapy for advanced EGFR-positive solid tumors
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
Denver, ColoradoAges 18 years+ - NCT06958328RecruitingPhase 3
Testing higher dose radiation for locally advanced pancreatic cancer
This trial tests if a higher dose of radiation therapy can help people with locally advanced pancreatic cancer after they've had 4–6 months of chemotherapy. It aims to improve cancer control without significantly increasing side effects.
Denver, ColoradoAges 18 years+ - NCT03257033RecruitingPhase 3
Gemcitabine through an artery versus by vein after radiation
This study tests whether giving gemcitabine directly into the artery feeding the pancreas (instead of through an IV) works better after you finish radiation therapy. It may help patients by improving how the medicine reaches the tumor while comparing side effects and outcomes between the two delivery methods.
Denver, ColoradoAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Denver, ColoradoAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Denver, ColoradoAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Denver, ColoradoAges 12 years+ - NCT06521554RecruitingPhase 1
Study of NVL-330 for HER2-altered advanced lung cancer
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Denver, ColoradoAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Denver, ColoradoAges 18 years+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Denver, ColoradoAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Denver, ColoradoAges 12 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Denver, ColoradoAges 18–75 - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Lakewood, ColoradoAges 18 years+ - NCT05508906RecruitingPhase 1
Test drug OP-1250 with other medicines in ER-positive breast cancer
This Phase 1b study tests OP-1250 (palazestrant) combined with other targeted medicines for ER-positive, HER2-negative advanced or metastatic breast cancer. It mainly looks at safety and correct dosing, but may also help shrink tumors or slow growth.
Aurora, ColoradoAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Aurora, ColoradoAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Aurora, ColoradoAges 18 years+ - NCT04862663RecruitingPhase 3
Capivasertib plus hormone therapy for HR+ breast cancer after progression
This Phase 3 trial studies capivasertib (a targeted pill) plus fulvestrant (a hormone injection) together with a CDK4/6 inhibitor to treat HR+ / HER2- advanced breast cancer that has returned or grown despite earlier hormone therapy. It may help by blocking growth signals linked to cancer cell survival.
Aurora, ColoradoAges 18–99
Hear when a new Locally Advanced trial opens near Denver, CO
We’ll email you when one opens near Denver, CO — at most once a week, no account needed, unsubscribe anytime.
Locally Advanced trials in other cities
Where these studies are running near Denver
Institutions with a site for the recruiting locally advanced studies listed above.
- Rocky Mountain Cancer Centers · 5 studies
- Sarah Cannon Research Institute · 5 studies
- University of Colorado Anschutz Medical Campus · 3 studies
- UCHealth Greeley Hospital · 2 studies
- UCHealth Highlands Ranch Hospital · 2 studies
- UCHealth Medical Center of the Rockies · 2 studies
- University of Colorado · 2 studies
- AdventHealth Littleton
What taking part in a locally advanced study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting locally advanced studies in Colorado.
Common questions
- Are there locally advanced clinical trials near Denver?
- Yes. We're currently tracking 47 recruiting locally advanced studies with a site near Denver, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced study near Denver?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Denver to take part?
- Not necessarily. These studies have a site near Denver, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced studies open near Denver regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.